Syntara Limited (ASX:SNT) Announces Positive Phase 2 Trial Results
Syntara Limited reports positive interim data from its Phase 2 trial of SNT-5505, indicating potential as a breakthrough treatment for myelofibrosis.
Category: Healthcare
Syntara Limited (ASX:SNT) Presents Interim Data from SNT-5505 Trial
Positive interim data from Syntara Limited’s SNT-5505 trial in myelofibrosis indicates significant clinical potential.
OpenLearning Limited (ASX: OLL) Announces Voluntary Suspension
OpenLearning Limited (ASX: OLL) has announced a voluntary suspension of its securities pending a key announcement regarding a related party loan facility.
Immutep Limited (ASX: IMM) Initiates Phase III Trial for Lung Cancer
Immutep Limited (ASX: IMM) has announced the initiation of TACTI-004, a Phase III trial for first-line metastatic non-small cell lung cancer.
Integral Diagnostics (ASX: IDX) Provides Merger Update
Integral Diagnostics receives ACCC clearance for its merger with Capitol Health, expecting implementation by 20 December 2024.
Doctor Care Anywhere Group PLC (ASX:DOC) Welcomes New CEO
Doctor Care Anywhere announces Laura O’Riordan as new CEO from January 2025, focusing on growth and quality in virtual healthcare.
Integral Diagnostics (ASX:IDX) Acquisition of Capitol Health Approved
Integral Diagnostics secures ACCC approval for Capitol Health acquisition, requiring divestiture of a clinic in the Melton region.
Anteris Technologies Ltd (ASX: AVR) Announces U.S. IPO Launch
Anteris Technologies Ltd (ASX: AVR) launches a U.S. IPO for 14.8 million shares to advance its innovative medical solutions.
LTR Pharma Limited (ASX:LTP) Secures A$25 Million Placement
LTR Pharma Limited secures A$25 million to advance its SPONTAN® treatment through regulatory processes in the U.S. market.
Visioneering Technologies, Inc. (ASX:VTI) Announces Voluntary Delisting
Visioneering Technologies, Inc. (ASX:VTI) has announced its intent to voluntarily delist from the ASX, seeking shareholder approval for the move.